Unknown

Dataset Information

0

LightSNiP assay is a good strategy for pharmacogenetics test.

ABSTRACT:

SUBMITTER: Cheli S 

PROVIDER: S-EPMC4451335 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

LightSNiP assay is a good strategy for pharmacogenetics test.

Cheli Stefania S   Pietrantonio Filippo F   Clementi Emilio E   Falvella Felicia S FS  

Frontiers in pharmacology 20150602

Similar Datasets

Unknown Brood parasitism: a good strategy in our changing world?
| S-EPMC4027383 | biostudies-literature
Unknown How Good Are We in Evaluating a Bedside Head Impulse Test?
| S-EPMC7722467 | biostudies-literature
Unknown RNA Interference Approach Is a Good Strategy against SARS-CoV-2.
| S-EPMC9862891 | biostudies-literature
Unknown Can a Point-of-Care Troponin I Assay be as Good as a Central Laboratory Assay? A MIDAS Investigation.
| S-EPMC4940482 | biostudies-literature
Unknown Impact of Previous Genetic Counseling and Objective Numeracy on Accurate Interpretation of a Pharmacogenetics Test Report.
| S-EPMC7920902 | biostudies-literature
Unknown Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
| S-EPMC5253119 | biostudies-literature
Transcriptomics Development of a potency test assay for CD34+ cell-based for acute myocardial infarction
2022-12-16 | GSE220865 | GEO
Unknown Loop technique with ink-dot marking test: An alternative strategy to the ink test.
| S-EPMC8302930 | biostudies-literature
Unknown Assay Techniques and Test Development for COVID-19 Diagnosis.
| S-EPMC7197457 | biostudies-literature
Unknown Nanoelectrokinetic-assisted lateral flow assay for COVID-19 antibody test.
| S-EPMC9112610 | biostudies-literature